Patent · US Active

Controlled-release CNP agonists with low initial NPR-B activity

US11389510B2 · kind B2 · utility

4Cited by

11References

6Claims

0Family size

Assignee

ASCENDIS PHARMA GROWTH DISORDERS A/S · DK

Inventors

Kennett Sprogøe · Rudegård, DK
Harald Rau · Würzburg, DE
Felix Cleemann · Mainz, DE
Ulrich Hersel · Heidelberg, DE
Caroline Elisabeth Rasmussen · Frederiksdal, DK

Key dates

Filing date	Jan 5, 2017
Grant date	Jul 19, 2022
Priority date	—
Expiry date	Jan 5, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.